PhRMA Member Company Efforts to Fight COVID-19

Return to the Industry’s latest efforts to beat COVID-19

Collaboration and Innovation is Vital

Decades of collaboration, investments in new technology, research and development and catalogued discovery, allowed us to respond to the pandemic with unprecedented speed. As we prepare for the challenges ahead, we must continue to support the R&D ecosystem that has allowed COVID-19 vaccines and treatments to be developed rapidly and safely.

An Overview of Member Support

Our members have led innovative R&D, provided financial support and in-kind donations to organizations, patients and first responders, and continue to work with health authorities to combat this global public health challenge. Below is a snapshot of ongoing efforts. You may filter by company and/or commitment type below.


Anchor ID: alkermes

As a leader in mental health, Alkermes recognizes there are many people who will be disproportionately impacted by COVID-19—particularly some of the most vulnerable members of society. Alkermes has made donations to five organizations in the local communities where it operates. These organizations focus on delivering food and support for low-income families and children, as well as seniors:

Council on Aging and the Wilmington School District, two essential communities during this time of need (Ohio)

Healthy Waltham, an organization providing food to children who normally depend on meals in schools and to seniors so they can remain at home and safe during this crisis (Massachusetts)

ALONE, a program focused on caring for the elderly population during this vulnerable and isolating period (Ireland)

Feeding America’s COVID-19 Response Fund, the largest hunger-relief organization in the United States (U.S. field-based employees)

In addition, Alkermes awarded grants to 10 nonprofit organizations from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonprofit organizations in their work to rapidly address pandemic-related needs for people living with addiction, serious mental illness, or cancer.


Anchor ID: amgen
Research and Development

Amgen and Adaptive Biotechnologies announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The mutually exclusive collaboration brings together Adaptive’s proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen’s expertise in immunology and novel antibody therapy development. Given the rapidly rising incidence of COVID-19 around the world, the companies will begin work immediately and finalize financial details and terms in the coming weeks.

Amgen is further exploring whether its medicine Otezla® (apremilast), an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials. Otezla inhibits the activity of phosphodiesterase 4 (PDE4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, Otezla is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients.


Amgen and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts and international relief efforts by Direct Relief and International Medical Corps.

The Amgen Foundation is also matching donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.

In addition, the Amgen Foundation seeks to advance excellence in science education and inspire the next generation of innovators:

  • In January, the Amgen Foundation and Harvard’s Faculty of Arts and Sciences launched LabXchange, a free online science education platform that provides users access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. As the founding sponsor, the Amgen Foundation awarded $11.5 million in grant funding to Harvard to deepen the impact of this new online learning platform across the globe.
  • The Amgen Foundation is the founding biology partner of the Khan Academy, a leading innovative and effective educational technology platform with over 70 million registered users across the globe.
  • Free online learning programs supported through both of these deep relationships are available to help students continue their science education during school closures, and can be accessed via the LabXchange and Khan Academy’s online learning websites.

Amgen’s subsidiary, deCODE Genetics, alongside colleagues from Iceland's Directorate of Health and the National University Hospital published online in the New England Journal of Medicine a population-based study of the early spread of the SARS-CoV-2 virus (causing COVID-19 disease) in Iceland. The results show that roughly 0.8% of the population at large is infected with several strains or clades of the virus supporting the concern that silent carriers spread the disease. This suggests that while the efforts of the public health system have been effective so far in mitigating the spread to date, more data, including massive population screening, will be key to informing efforts to contain the virus in Iceland in the long run. This work to identify the various mutations will also be important in Amgen’s collaboration with Adaptive to find antibodies that are broadly effective against different strains of SARs-CoV-2 and the various mutations those strains carry. Once the best antibody or antibodies are identified, Amgen will apply its expertise in genetics, immunology, antibody engineering, and manufacturing to optimize, develop, and produce a therapy designed to treat and prevent COVID-19 infection.


Anchor ID: astellas
Research and Development

Astellas has coordinated with government bodies involved in COVID-19 research, including providing our compounds upon request. In Japan, we have provided compounds in response to a request from the Ministry of Health, Labour and Welfare and National Institute of Infectious Diseases to cooperate in the “Basic Screening Plan for Drugs for Coronavirus Disease.” In addition, we are conducting collaborative research with The Japanese Association for Infectious Diseases for the purpose of exploring the risk factors relevant to severe COVID-19 in the Japanese population, and we hope that the results of this collaborative research will be leveraged in the diagnosis, treatment, and prevention of COVID-19 in the future.


Astellas Pharma US (Astellas) and the Astellas Global Health Foundation have provided a combined commitment of more than $2.7 million of COVID-19 financial assistance, in aggregate, to meet the urgent demand for resources to help patients, healthcare workers and first responders.

At a national level in the United States, Astellas has helped humanitarian organizations working to support communities due to the COVID-19 outbreak. This includes Astellas donations to Americares, the American Red Cross, and Direct Relief to help their emergency efforts. Additionally, through its corporate charitable donations, Astellas has provided support to non-profit patient organizations to actively combat isolation and other negative impacts of the COVID-19 pandemic.

Astellas has also coordinated opportunities to mobilize equipment, personal protective equipment (PPE), and blood donations in alignment with Centers for Disease Control and Prevention guidance, as well as employee contributions and volunteerism to meet the critical demand for time and resources where needs are most pressing. In 2020, the Astellas Global Health Foundation provided more than $2 million in COVID-19 relief to six organizations impacting more than 725,000 lives in vulnerable communities in seven countries. Additionally, the Astellas Global Health Foundation will award an additional $750,000 in COVID-19 recovery funding two organizations that will impact more than 800,000 lives in vulnerable communities in two countries in 2021.

In Italy, our group company, Astellas Pharma S.p.A., made a donation worth 174,800 euros for the necessary supply of goods to public medical institutions and NPOs.  In Spain, our group company, Astellas Pharma S.A., made a donation worth 200,000 euros to the country’s health ministry for the necessary supply of goods to medical institutions.


Locally at Astellas’ US headquarters in Illinois, the company has partnered with multiple state organizations with their response to COVID-19, as a Founding Partner to the Governor’s Illinois COVID-19 Response Fund and the Illinois Biotechnology Innovation Organization (iBIO) COVID-19 PPE Relief Fund.

Astellas has responded to requests from the European Federation of Pharmaceutical Industries Associations (EFPIA) and the Innovative Medicines Initiative (IMI) to cooperate in the “Activities Aimed at Developing Drugs for the Novel Virus” and providing consultation on countermeasures. Astellas Pharma Europe Ltd. is a member of the CARE (Corona Accelerated R&D in Europe) Consortium, the largest initiative in Europe addressing the challenges of COVID-19.

As part of our membership of the non-profit organization, TransCelerate BioPharma Inc., Astellas is participating in the COVID-19 Task Force, alongside 20 other biopharmaceutical member companies, to share industry best practices in managing the continuity of clinical trial operations during the global COVID-19 pandemic while ensuring patient safety and maintaining study integrity.

To assist healthcare systems coping with increasing demands presented by the escalation of COVID-19 around the world, Astellas employees who are medically qualified practitioners, medically qualified volunteers or individuals seeking to support organizations in their local communities may utilize paid volunteer time off. Astellas is committed to ensuring patient safety and alleviating the strain on healthcare resources around the world and the company continues to assess the ongoing situation. To learn more about Astellas’ global and local support, click each link.


Anchor ID: astrazeneca
Research and Development

Recognizing the urgent need for a vaccine to defeat the coronavirus, AstraZeneca joined forces with the University of Oxford in early 2020, combining world-class expertise in vaccinology with AstraZeneca’s global development and manufacturing capabilities. Together, they developed a highly-effective vaccine, Vaxzevria (formerly AZD1222).

The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

As of December 2021, Vaxzevria (known as COVID-19 Vaccine AstraZeneca in the UK) has been granted a conditional marketing authorization or emergency use in 85 countries across six continents. More than 2.5 billion doses of the vaccine have been supplied to over 170 countries worldwide, including more than 130 countries through COVAX. AstraZeneca’s fight to end COVID-19 didn’t stop with their vaccine development. The Company also developed a long-acting antibody (LAAB) combination, EVUSHELD (formerly AZD7442), which was authorized for emergency use in the US in December 2021 for pre-exposure prophylaxis (prevention) of COVID-19, and has the potential to treat COVID-19.

For the latest on AstraZeneca’s efforts, please visit


AstraZeneca is working with governments and partners around the world to ensure broad and equitable access to its vaccine. AstraZeneca was the first global pharmaceutical company to join the COVID-19 Vaccines Global Access (COVAX) initiative in June 2020, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. COVAX is a global platform helping to accelerate the development, production and equitable access to COVID-19 vaccines, regardless of income, by providing logistical and financing support to participating countries.

As of December 2021, more than 260 million doses of AstraZeneca’s COVID-19 vaccine have been delivered through COVAX to over 130 countries. This accounts for approximately 90% of the COVAX supply to date,  two thirds of which have gone to low- and middle-income countries.


AstraZeneca is dedicated to working in collaboration with scientists, governments, multilateral organizations and manufacturers around the world to fight COVID-19 and remains committed to broad, equitable and affordable access to its vaccine.


Anchor ID: bayer

Bayer is donating 3 million tablets of the drug Resochin (chloroquine phosphate) to the U.S. Government to support its efforts in the fight against COVID-19. Resochin, a product discovered by Bayer in 1934 and indicated for prevention and treatment of malaria, may have potential in treating patients with COVID-19 infection, based on new and limited data from initial preclinical and evolving clinical research conducted in China. Bayer has also made a $250,000 commitment to the Berkeley Relief Fund, an initiative by the Berkeley, California, City Council to provide emergency relief grants for small businesses, nonprofit arts organizations and worker rent support. In addition, Bayer has provided substantial financial donations and donations of several medicines to the Chinese Red Cross, which is working with Chinese health authorities to coordinate the deployment of aid measures to support those affected by the outbreak of COVID-19 there. Bayer is also supporting hospitals in Lombardy, Italy, with a donation of one million euros. The aid is being added to an aid fund that the regional authorities in Lombardy have set up to help procure urgently needed equipment for intensive care units in hospitals with the greatest needs.


Bayer will continue to provide affected regions and countries with rapid and unbureaucratic assistance as part of its corporate social responsibility.


Anchor ID: biogen

The Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic. The funds will be used to address immediate critical needs, with the majority of donations going to support non-profit organizations in the U.S., including Massachusetts and North Carolina, in Italy and in other impacted countries worldwide. This donation will be used to help expand testing options, ease the strain on medical systems, provide training for front line health workers and support access to necessities like food. This adds to the donation made by Biogen China to the Red Cross Society of China. The company has also provided medical equipment and supplies to Partners HealthCare in Massachusetts, to help diagnose COVID-19 in a greater number of people. Partners HealthCare is one of the largest providers of healthcare services in the Boston area.


Biogen will also be supporting Massachusetts General Hospital and Brigham and Women’s Hospital directly as they work on the front line to treat and contain the virus.

Boehringer Ingelheim

Anchor ID: boehringer_ingelheim

At a local level, BI is redeploying the hard-working employees who support its U.S. cafeterias to prepare meals to donate to those whose access to food is a struggle. The company’s U.S. Boehringer Ingelheim Cares Foundation (BI Cares), an independent nonprofit organization, is making monetary donations and donating urgently needed medicines for patients through its non-governmental organization (NGO) partners. BI Cares added a new cause to its Matching Gifts Program to provide BI U.S. employees the opportunity to double the impact of their charitable giving to a fund being used to prevent the spread of and help those affected by COVID-19. Additionally, the Foundation is conducting employee engagement campaigns to raise funds to donate to nonprofits near our U.S. sites that are distributing groceries to food insecure individuals and families.

BI's Global Support Program aims to bring more financial relief, protective materials and medicine donations to health care institutions and communities in need around the world. The program focuses on four areas:

  • Donations: BI has made available €7 million for financial and in-kind donations for local emergency aid across the globe. They are also working with local organizations that use financial and medicine donations to organize help for patients in their communities.
  • Research for COVID-19 therapies: Since January, BI has freed up a growing team of currently more than 100 highly engaged scientists from all areas of research and development, to work on projects aimed at finding potential treatment solutions for COVID-19. As this work evolves, BI will commit further experts from multiple disciplines, as well as increased lab capacity.
  • Volunteering: In many communities, helping hands from volunteers, for example with a medical or nursing background, are urgently needed. BI offers all 51,000 employees the opportunity to take up to 10 days of paid leave to join approved external organizations as a volunteer to bring COVID-19 relief.
  • Making More Health relief fund: A €580,000 relief fund has been launched to support the global Making More Health network of social entrepreneurs in Kenya and India, as well as the communities in which they live and work.

Together with life science companies around the world, BI joined the COVID-19 Therapeutics Accelerator of the Bill and Melinda Gates Foundation to fight the pandemic. The collaboration aims to accelerate the development, manufacture, and delivery of vaccines, diagnostics and treatments for COVID-19. Boehringer Ingelheim will contribute its historic molecules, which the Accelerator will be testing. To identify candidate compounds, the Accelerator will take a three-pronged approach: testing approved drugs for activity against COVID-19, screening compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.


Boehringer Ingelheim (BI) is standing together with all parties to support the fight against the COVID-19 pandemic while taking action to protect employees’ health and safety. BI is continually assessing what additional measures they can take to help its patients and communities. The company’s focus remains on assuring the ongoing supply of BI medicines for its human and animals patients in the U.S. and around the world. In addition, BI made financial contributions totaling over $1 million to protect health care professionals in the critical services they are providing to patients. BI donated medicines and medical supplies. Its teams are conducting a computational screen of our entire library of over one million compounds and are investigating the activity of selected existing small molecule compounds from our former antiviral research against SARS-CoV2.

Bristol Myers Squibb

Anchor ID: bristol_myers_squibb

Bristol Myers Squibb and the Bristol Myers Squibb Foundation, a 501(c)(3) organization, are actively and separately contributing to relief efforts around the world. Together, Bristol Myers Squibb and the Bristol Myers Squibb Foundation have contributed more than $31 million in financial support and needed products (e.g. PPE and medical equipment) to relief efforts in 45 countries.

The Bristol Myers Squibb Foundation has supported nearly 50 organizations in the U.S. and more than 150 organizations globally that care for patients and support those on the frontlines of the COVID-19 response. In addition, the Foundation has contributed funding to support the work of more than 40 patient advocacy groups and professional societies. Bristol Myers Squibb is engaging with more than 250 patient and professional organizations to support research, education, and other efforts to benefit patients.


Our contributions to COVID-19 research reflect collaborative and productive discussions internally and with the broader life sciences community about how we can have the greatest impact given our company’s areas of strength, and we will continue to engage in this way to support the significant and rapid effort underway as the science evolves. This has included participation in several cross-industry groups and public-private partnerships designed to foster collaboration and coordinate industry response efforts, and thereby accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19. Partnerships include with Rockefeller University, the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program and the Bill & Melinda Gates Foundation’s COVID-19 Therapeutics Accelerator. BMS also organized a COVID-19 Testing Industry Consortium with 24 other healthcare companies that aims to inform, improve, innovate, and accelerate various aspects of testing for COVID-19.

CSL Limited

Anchor ID: csl_limited
Research and Development

In 2020, CSL worked with the University of Queensland in the early stages of its UQ-CSL v451 COVID-19 vaccine candidate. A Phase I clinical trial showed that the vaccine elicited a robust response towards the virus and had a strong safety profile. However, following consultation with the Australian Government, CSL did not progress the vaccine candidate to Phase II or Phase III clinical trials due to the partial immune response causing an unexpected interference with certain HIV testing procedures. In support of the University of Queensland program and a number of other research programs around the world, Seqirus provided its well-established adjuvant technology – MF59®. MF59® is used in CSL’s adjuvanted seasonal flu vaccine for the over-65 age group, one of the most vulnerable populations to COVID-19. Adjuvants can help improve immune response and reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly. CSL Behring launched a clinical trial into the use of Garadacimab (CSL312), our factor XIIa antagonist monoclonal antibody, to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19–related pneumonia. A Phase II trial to assess the safety and efficacy of the potential treatment was rapidly completed; and whilst Garadacimab was found to be safe for these critically ill patients, the treatment was not effective in reducing severe complications of COVID-19. CSL is evaluating additional assets in its portfolio, and partnerships with external researchers, for potential use in the fight against COVID-19. Our acumen and expertise across vaccine, monoclonal antibody, recombinant and plasma technology platforms, our manufacturing capabilities and partnerships, along with a therapeutic focus in immunology and respiratory, all align with the scope of this disease and, most importantly, our ability to contribute to the development of potential vaccines and treatments.


CSL Behring co-founded the CoVIg-19 Plasma Alliance, an unprecedented industry of 11 plasma companies, including Takeda, across 13+ countries and five continents, to develop a potential plasma-derived hyperimmune therapy for treating COVID-19. The one-year collaboration concluded in April 2021 after a Phase III clinical trial of the potential therapy did not meet its endpoints. CSL rapidly established dedicated COVID-19 vaccine teams across its business units and transitioned elements of its Australian manufacturing capacity, at both our CSL Behring Broadmeadows and Seqirus Parkville facilities, to manufacture 50 million doses of AstraZeneca’s COVID-19 vaccine for use in Australia and regional countries. First doses were rolled out in March 2021 with over 33 million doses released at the end of January 2022.

Daiichi Sankyo

Anchor ID: daiichi_sankyo
Research and Development

Daiichi Sankyo is actively engaged in various R&D measures and initiatives to combat the spread of COVID-19, including:

Vaccines and therapeutics: Daiichi Sankyo’s R&D team in Japan established a company-wide task force to promote research and development of vaccines and therapeutic agents targeting COVID-19. By leveraging their past and present research properties, technologies and accumulated R&D knowledge, and in collaboration with external institutions, they are proactively involved in the development of a treatment for COVID-19.

Supply Chain and Clinical Trials: Daiichi Sankyo is working tirelessly to ensure ongoing safe supply of their medicines to the patients who need them. Furthermore, their Clinical Trials Task Force continues to provide support for investigators based on the most recent guidance on the conduct of clinical trials of medical products during the COVID-19 pandemic issued by several global health authorities, such as the U.S. Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency and the European Medicines Agency.

Learn more about Daiichi Sankyo’s efforts here.


Relief funding: Daiichi Sankyo Group companies have allocated financial donations to a variety of organizations including to the COVID-19 Solidarity Response Fund, the Chinese Red Cross Association, the American Red Cross, Americares and various non-profit organizations dedicated to oncology patients globally. Daiichi Sankyo also donated protective personal equipment to a California hospital system.

Volunteerism and Employee Support: Daiichi Sankyo, Inc. is allowing employees with appropriate medical or health care credentials to take paid time away from work to volunteer alongside health care providers to support patient care and to help alleviate the pressure on those on the frontlines. In addition, their affiliates globally have established a wide variety of support programs and activities to help employees and consultants navigate through this crisis.

Eisai, Inc.

Anchor ID: eisai_inc
Research and Development

Eisai is collaborating with a variety of companies, health authorities and nonprofit organizations on clinical research projects designed to treat COVID-19. They have donated compounds developed in-house, as well as pharmaceutical ingredients they believe will be helpful in the creation of potential treatments.

These research projects include the following collaborations:

  • Eisai supplied its investigational Toll-Like Receptor 4 (TLR4) inhibitor eritoran (E5564), created internally and previously developed as a potential treatment for sepsis, to the international network REMAP-CAP-COVID (Randomized, Embedded, Multi-factorial, Adaptive Platform-Community Acquired Pneumonia COVID), which aims for novel coronavirus medicine development. Eisai and the Global Coalition for Adaptive Research (GCAR), in collaboration with the University of Pittsburgh Medical Center, began an international collaborative clinical trial was initiated in October 2020. By suppressing the most upstream TLR4 activity, which controls production of multiple cytokines, the trial hopes the cytokine storm in patients can be suppressed and pneumonia can thus be prevented from becoming severe.
  • Eisai provided its unique collection of about 2,650 natural product compounds to the Scripps Institute in the U.S. for constructing a compound library for the development of treatments. This effort is part of consortium of life science companies titled “COVID-19 Therapeutics Accelerator” initiated by the Bill & Melinda Gates Foundation and formed with collaboration from Wellcome and MasterCard. Eisai will also be providing its vaccine adjuvant (E6020) for boosting antibody production.
  • Eisai supplied active pharmaceutical ingredients to the Japanese Institute of Infectious Diseases in response to their request for active pharmaceutical compounds for screening of remedies for the novel coronavirus.
  • The “Study of Smartphone Application Spo2 Monitoring System Linking With ‘LINE’ for COVID-19 Patients in Home/Hotel Recuperation” has been selected by the Japan Agency for Medical Research and Development (AMED) for its empirical and modification research support for the “FY2020 Program to Develop Countermeasure Technologies against Viral and Other Infectious Diseases.” This experimental study was initiated under a joint research agreement with Eisai, Allm Inc. and the Tokyo Medical and Dental University.
  • Gimsilumab, the anti-GM-CSF antibody which Eisai licensed to Roivant, is being tested in a placebo-controlled, double-blind study conducted by Roivant in the U.S. on acute respiratory distress syndrome (ARDS) caused by the novel coronavirus. Eisai is supporting the promotion of clinical trials.

Eisai has provided millions of dollars in donations and medical supplies globally to help in the battle against COVID-19. These efforts include:

  • In the U.S., Eisai has donated more than $1 million in funding to health care institutions and nonprofit patient organizations that have distinct COVID-19 needs.
  • In Europe, they have donated €945 thousand in funding to professional organizations targeting COVID-19 such as World Health Organization, as well as to support health care providers and vulnerable COVID-19 communities in the UK, Italy, Germany, Spain, Belgium, France, Portugal and the Slovak Republic.
  • In China, they have donated 1 million yuan to the Wuhan Charity Federation NPO, as well as provided local health care providers with medicines and medical relief supplies.
  • In Asian countries and other countries outside of China, they have donated 11.8 million rupees to federal emergency funding in India and will also provide funding and supplies to support organizations such as community chests in Korea, Thailand, Vietnam, Indonesia, the Philippines, Malaysia, Singapore and Mexico.
  • In African countries, Eisai has committed the equivalent of $1 million USD in aid over the next year to support the control of the spread of the novel coronavirus infection, in addition to the prevention of delays of elimination activities for neglected tropical diseases. In cooperation with the Drugs for Neglected Diseases initiative, Eisai provided personal protective equipment to core hospitals in Africa for research of and countermeasures against infectious diseases.

Driven by its human health care mission of giving its first thought to patients and the benefits health care provides, Eisai Company Ltd. is working on a variety of global initiatives in the fight against the COVID-19 pandemic. The company is continuing to ensure the manufacturing and supply of their medicines to patients and have implemented safeguards to protect the health and wellbeing of all employees through safe social distancing lab practices, limited business travel and flexible at-home working schedules.

For additional information, please visit:

Eli Lilly and Company

Anchor ID: eli_lilly_and_company
Research and Development

Lilly has utilized the full force of its expertise to provide therapy options for all points of a COVID-19 journey, helping to keep patients from progressing to hospitalization, and to offer options to those who have been hospitalized. Lilly developed the first monoclonal antibody authorized for Emergency Use (EUA) by the U.S. Food and Drug Administration (FDA)- bamlanivimab, followed by the authorization of bamlanivimab with etesevimab and, most recently, bebtelovimab. Bebtelovimab, which maintains binding and neutralizing activity against all known variants and variants of concern, including Omicron and BA.2, is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. In addition to three monoclonal antibodies, the FDA has authorized baricitinib under emergency pathways. As of Q1 2022, over 700,000 patients have been treated with Lilly's monoclonal antibodies in the U.S., potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths during the worst of the pandemic. Additionally, approximately 100,000 doses of bamlanivimab alone or bamlanivimab with etesevimab have been donated to 9 low- to lower-middle-income countries (LMIC). Click here for resources related to Lilly's COVID-19 efforts.


Lilly is committed to doing everything possible to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic. The company announced it has entered into an agreement with AbCellera to co-develop antibodies for the potential treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. Lilly and Junshi Biosciences have also entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19. Lilly is also testing existing medicines with potential to address COVID-19, including through an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to participate in NIAID's Adaptive COVID-19 Treatment Trial.


Lilly is also closely monitoring its supply chain and does not currently anticipate shortages for any of their medicines, including all forms of insulin. Additionally, Lilly and the Lilly Foundation are actively engaged with community partners to address new and complex challenges arising from the coronavirus, including the economic impact on vulnerable people. Find the latest information on Lilly’s efforts here.

New $35 co-pay now available through Lilly Insulin Value Program in response to COVID-19 crisis in U.S. Learn more here.

EMD Serono

Anchor ID: emd_serono

Merck KGaA, Darmstadt, Germany is committing to support the investigation of potential therapeutics for COVID-19. The company donated a supply of interferon beta-1a (Rebif®) to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. To date, Merck KGaA, Darmstadt, Germany’s interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.

The company is also supporting those impacted by the COVID-19 pandemic – whether patients, the community, or those on the front lines. Merck KGaA, Darmstadt, Germany donated 2 million respiratory masks in the US, Germany, France and other countries to support healthcare workers. The company supported China’s fight against the coronavirus with multiple donation efforts in cash and kind to three well respected local charitable organizations in order to support much needed medical aid. This includes products to support local institutions and invitro diagnostic manufactures to accelerate research, as well as virus diagnosis and testing efforts and personal protective equipment.


Merck KGaA, Darmstadt, Germany is contributing to scientific progress to fight COVID-19 through collaborations and research funding. Together, they are collaborating with the Bill & Melinda Gates Therapeutic Accelerator to quicken the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19. Overall, the spread of the coronavirus also stresses the importance of pandemic preparedness – a topic that Merck KGaA, Darmstadt, Germany continues to support with the €1 million Future Insight Prize.


Merck KGaA, Darmstadt, Germany* is dedicated to serving patients, scientists and health care providers in the U.S. and around the world – now more than ever. They actively contribute resources as well as dedication and expertise to fight the COVID-19 pandemic, while continuing to supply medicines for those who are among the most vulnerable in the pandemic—patients affected by serious diseases.

Merck KGaA, Darmstadt, Germany is dedicated to continue to provide patients living with serious diseases with the medication they need each and every day by providing continuity of treatment for clinical trial participants and supplying medicines for those most vulnerable in this pandemic.

*The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada.

Genentech, a member of the Roche Group

Anchor ID: genentech_a_member_of_the_roche_group
Research and Development

Genentech and Roche are contributing to the fight against the global pandemic by delivering diagnostic tests and solutions, developing treatment options, and forging collaborations. They have sponsored or supported several clinical trials evaluating existing medicines or investigational molecules for the potential treatment of COVID-19 in hospitalized adults and pediatric patients. Roche Diagnostics has been granted Emergency Use Authorization in the U.S. by the Food and Drug Administration for a portfolio of lab, point-of-care, and at-home rapid antigen tests to detect the virus' genetic signature or antibodies to identify an immune response. For additional information, please visit:


Genentech and the Genentech Foundation committed $42 million to help address the devastating impact of the COVID-19 pandemic. This support included emergency response grants and funds for longer-term recovery efforts, with an emphasis on low-income households and communities of color. Learn more about Genentech's approach to giving to help address critical health needs, strengthen schools and provide community grassroots support.


Genentech and Roche are contributing their scientific knowledge and research expertise in infectious diseases and in antibody-based therapeutics as well as their skilled workforce and specialized manufacturing capabilities. They believe partnerships are imperative to combat this virus and have sought out meaningful cooperation with industry peers. They are collaborating with Regeneron to develop, manufacture, and distribute Regeneron’s COVID-19 antibody cocktail REGN-COV® (casirivimab and imdevimab) to people around the globe. They continue to work with government agencies, health authorities, industry peers, and other key stakeholders across the global healthcare ecosystem to defeat COVID-19.


Addressing health inequity and reducing disparities and barriers to clinical research is increasingly central to Genentech’s mission to improve patient health outcomes. Genentech is committed to:

  • Generating evidence that matters for more patients by incorporating enhanced population, science-driven strategies, and inclusive clinical research action plans across our research and development programs.
  • Overcoming health disparities through integrated solutions and deepening engagements with all stakeholders to further health equity for all.
  • Being a leader and partner of choice in advancing health equity.

Gilead Sciences

Anchor ID: gilead_sciences
Research and Development

Gilead is harnessing decades of antiviral expertise to rapidly respond to the COVID-19 pandemic.

Gilead has initiated Phase 3 studies to evaluate the safety and efficacy of the investigational antiviral remdesivir in adults diagnosed with COVID-19. The company is also supporting additional clinical trials globally with study drug.

Additionally, Gilead accelerated and expanded manufacturing of remdesivir to increase its available drug supply as rapidly as possible, setting a goal of manufacturing more than 1 million treatment courses by the end of 2020 and several million treatment courses in 2021.


Gilead established a $20 million philanthropic fund, the Gilead CARES (COVID-19 Acute Relief and Emergency Support) Grantee Fund, to support nonprofit organizations impacted by the COVID-19 crisis, alongside other community donations.

Additionally, Gilead recently announced that it will donate existing supply of remdesivir, equaling 1.5 million individual doses for the treatment of patients with severe COVID-19 infection globally, for clinical trials, compassionate use or expanded access programs, and following potential future regulatory authorizations.


Across all its efforts, Gilead is collaborating with government agencies, academic institutions, non-profit organizations, and individual researchers and clinicians, to share information and efficiently deploy resources globally to help patients and communities fighting COVID-19.


As a company, Gilead is committed to putting its resources and research to bear to advance treatments that may help in the global response to this public health emergency.


Anchor ID: glaxosmithkline
Research and Development

GlaxoSmithKline (GSK) is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. GSK is taking the following actions to support the global response to COVID-19:

GSK and Sanofi are entering into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi contributed its S-protein COVID-19 antigen, which is based on recombinant DNA technology. GSK contributed its proven pandemic adjuvant technology to the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

GSK has confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system in 2021 to support the development of multiple adjuvanted COVID-19 vaccine candidates. This follows completion of a review conducted across the company's global supply network. GSK will manufacture, fill and finish adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe.

GSK has evaluated its marketed medicines and those in development to determine if any could be used beyond their current indications and evaluating options to make available specialized laboratory space to help in research and testing of COVID-19.

  • Through this screening process, GSK has identified otilimab, an anti-GM-CSF (anti-granulocyte macrophage colony-stimulating factor) monoclonal antibody, currently in phase III development for rheumatoid arthritis, as a potential candidate molecule for patients who have been hospitalized with severe pulmonary COVID-19 related disease. These severe secondary complications of COVID-19 are caused by an over-reaction of the body’s immune system to fight the virus and GSK believes that otilimab can help control this process and plans to start the phase II study imminently.

GlaxoSmithKline (GSK) donated $10 million to WHO and the UN Foundation's COVID-19 Solidarity Response Fund to support WHO and partners prevent, detect and manage the pandemic, particularly where the needs are the greatest.

GSK has donated surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees, to enable those with medical or specialist expertise to provide support to frontline health workers and national governments.


GSK entered into a collaboration to find coronavirus solutions with Vir Biotechnology. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines. On May 21, 2021, the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) issued a positive scientific opinion following the referral of our monoclonal antibody candidate to the CHMP. The EMA’s recommendations can now be used to support national advice on the possible use of this monoclonal antibody before a marketing authorization is issued. On May 26, 2021 we received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the same monoclonal antibody for the treatment of mild-to-moderate COVID-19 in high risk adults and pediatric patients. A second antibody from our collaboration with Vir is also being investigated as a potential COVID-19 treatment. A phase 1/2 study in patients with mild to moderate COVID-19 is underway at multiple sites across the UK, as part of the NHS-supported AGILE platform study of potential COVID-19 therapeutics.


GSK and Vir are working to make sotrovimab commercially available to U.S. patients with the intent that all appropriate patients will have access to it, with little to no out-of-pocket costs. Patients and healthcare professionals can access more information about eligibility, availability and financial support at or by calling 866-GSK-COVID (866-475-2684).


Anchor ID: incyte
Research and Development

Incyte’s ruxolitinib has been studied in patients with COVID-19.


In March 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs, with disease severity requiring mechanical ventilation. Improvement in mortality for each dose compared to placebo (primary endpoint), while trending toward positive, was not statistically significant for the overall study population. However, results showed significant improvement in mortality in U.S. study participants at both doses, and in the overall population when data from both treatment arms was pooled. For more information, please see our press release.


In December 2020, Incyte announced results from the RUXCOVID (NCT04362137) trial, testing ruxolitinib in patients hospitalized with severe COVID-19 but whose disease did not yet require intubation. Initial data showed that treatment with ruxolitinib plus standard-of-care (SoC) did not reduce complications in these patients with COVID-19 associated cytokine storm. For more information, please see our press release.


Incyte is committed to supporting its local communities, particularly during this unprecedented time of need. Incyte has made several contributions, including:

  • Supplies, including personal protective equipment (PPE), from Incyte’s laboratories in Wilmington, DE, have been donated to local Delaware hospitals.
  • Incyte has also donated to the Food Bank of Delaware to cover the costs of increased food distribution and pre-made weekend meal kits.
  • Incyte Italy has made a donation to fund the purchase of hospital equipment and goods to support patients, hospitals, healthcare facilities and providers in the critically affected Lombardy region.
  • Along with other companies, Incyte supported The Leukemia & Lymphoma Society COVID-19 Patient Financial Aid program, aimed at providing financial assistance to eligible patients for food, non-medical and other day-to-day expenses that may arise due to loss of income.

Incyte takes public health very seriously and is closely monitoring the evolving COVID-19 pandemic. The company’s primary focus is on ensuring patients have access to the medicines they need while safeguarding the health and safety of its employees.

To learn more about Incyte’s COVID-19 response, click here.

Johnson & Johnson

Anchor ID: johnson_johnson
Research and Development

Building on the groundbreaking science and scalable production platforms that were used to construct Ebola, Zika and HIV investigational vaccine candidates, Johnson & Johnson is committed to bringing a safe and effective vaccine to the public on a not-for-profit basis for emergency pandemic use as soon as early 2021, provided the investigational vaccine is safe and effective. Johnson & Johnson has selected a COVID-19 vaccine candidate from constructs they have been working on since January 2020 and is working closely with global partners to identify devices and potential treatments that could contribute to providing immediate relief to the current pandemic.

On August 5, 2020 Johnson & Johnson announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the FDA.

The company’s preclinical data, which were published in the journal Science, validated the preclinical vaccine challenge model and showed that prototype DNA vaccines were able to elicit an immunity.

On July 30, 2020 Johnson & Johnson announced the findings of the preclinical study conducted in collaboration with Beth Israel Deaconess Medical Center. The data, published in Nature, show the investigational vaccine elicited an immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection in all the non-human primates (NHPs) involved in the study.

Based on this total package of pre-clinical results, the company initiated Phase 1/2a studies, which it kicked off in late-July.

Johnson & Johnson is in discussions with the National Institutes of Health with the objective to start the Phase 3 clinical trial ahead of its original schedule, potentially in late September, to evaluate the effectiveness of the investigational vaccine.

Through its Innovation Centers and Business Development teams across the Johnson & Johnson global innovation network, Johnson & Johnson has been reviewing novel science and technologies to help address the pandemic. Having screened over 100 ideas related to potential vaccines, antiviral therapeutics and diagnostics/consumer aids since the outbreak began, several are under detailed evaluation. More than 60 resident companies in their global incubator network Johnson & Johnson Innovation – JLABS are currently exploring novel approaches to help address the COVID-19 pandemic.

The COVID-19 pandemic is disproportionately impacting communities of color. While no single organization can solve the full range of challenges exacerbated by the global public health crisis of the coronavirus pandemic, Johnson & Johnson is working to advance racial and ethnic health equality through a series of targeted COVID-19 programs and collaborations.

Johnson & Johnson is exploring ways to contribute to the body of research generating deeper and more granular insights into how COVID-19 is impacting diverse communities. This research, which will be conducted at a national and county level, will be used to develop shareable insights and resources, submitted for publication, shared with policymakers and disseminated as a public good. Johnson & Johnson hopes to collect some of this information through our partnerships on clinical trials.

They are also working directly with many branches of government, as well as partnering with advocates, NGOs and leaders like the Congressional Black Caucus, to lend its voice, expertise and perspective to improving health outcomes in Black communities. Johnson & Johnson testified before the U.S. House of Representatives Energy and Commerce Committee on its vaccine research and manufacturing efforts. Additionally, Johnson & Johnson was one of a few companies to sign on to a coalition letter to Congressional leaders in the U.S. calling for increased and improved data collection and dissemination for COVID-19 patients. They have taken the position that without timely and systematic collection of this health data, we will not be able to fully understand – and address – the pandemic and its disproportionate impact on communities of color.

In company-sponsored COVID-19 clinical trials, Johnson & Johnson is leveraging a special engagement strategy that includes a digital and community outreach plan to provide resources to help identify opportunities to participate in clinical research, identifying and implementing ways to reduce operational barriers and patient burden, applying lessons from other trial recruitment efforts and educating Black and Brown communities across the U.S. about clinical trials and the importance of participation.


Johnson & Johnson is delivering critical support for communities and health workers on the front lines. At the outset of the pandemic, the Johnson & Johnson Family of Companies and Johnson & Johnson Foundation committed $50 million to support and supply frontline health workers. This commitment expands upon a $250 million multi-year commitment made earlier this year to support those at the frontlines.


Johnson & Johnson has been collaborating with regulators, health care organizations, institutions and communities worldwide to help ensure research platforms, existing science and outbreak expertise can be maximized to stem this public health crisis.

Johnson & Johnson is working in collaboration with the >Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine candidate for COVID-19.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing.

The Janssen Pharmaceutical Companies of Johnson & Johnson have entered into collaborations with Emergent BioSolutions, Inc. and Catalent Biologics to support the manufacturing of its lead investigational vaccine candidate. These are the first in a series of prospective global collaboration agreements designed to further Johnson & Johnson’s goal to supply more than one billion doses of the vaccine globally through the course of 2021, provided the investigational vaccine is safe and effective.


Johnson & Johnson is mobilizing its global reach, deep scientific expertise, extensive partnerships and financial stability to address the critical needs of families, communities, health care professionals and its employees around the world.

To learn more, visit


Anchor ID: lundbeck
Research and Development

With evidence showing some people with serious mental illness are at risk for more severe COVID-19 health outcomes, plus questions regarding the long-term neurological effects of the virus, the pandemic underscored the urgent need for increased understanding of central nervous system disorders and new medicines for brain diseases.

In Denmark and La Jolla, Calif., Lundbeck scientists have continued research and drug discovery activity, pursuing novel therapies for brain diseases. In collaboration with research partners across the globe, Lundbeck’s drug development team implemented innovative, responsible processes that allowed clinical trials for high-need diseases like Alzheimer’s disease and post-traumatic stress disorder to continue uninterrupted.


To support vaccination efforts, Lundbeck sponsored a vaccination clinic near its Chicago-area headquarters. The community clinic was developed in collaboration with area public health officials and designed to aid a high-need community that was particularly hard-hit by the virus and its economic impacts. Prior to the establishment of the clinic, the community had low vaccination rates, and Lundbeck’s donation allowed for expanded community outreach and vaccine education. Lundbeck colleagues had the opportunity to volunteer at the vaccination clinic and play a direct role in supporting the community.

In addition, Lundbeck North America committed $1 million in support of COVID-19 relief efforts to COVID Response Funds in regions where the company a meaningful presence, with significant donations from the Lundbeck US Charitable Fund to Response Funds in Illinois, Seattle and San Diego. These donations enabled local nonprofit organizations to provide interim housing and shelter, direct financial assistance, and primary healthcare and mental healthcare services to vulnerable community members. The Lundbeck US Charitable Fund also made a significant donation to the Center for Disaster Philanthropy COVID-19 Response Fund, which focuses on nonprofit organizations working directly to support health care workers and respond to the pandemic among the most vulnerable populations.

The company also took action to bolster our health care system’s ability to respond to the pandemic through support of the Illinois Biotechnology Innovation Organization (iBio) COVID-19 PPE Relief Fund, which secured protective medical products for Illinois-based health care workers and first responders. And the Lundbeck Foundation, which owns 70% of Lundbeck, earmarked DKK 30 million (USD 4.3 million) for research projects targeting the coronavirus pandemic.

Lundbeck’s La Jolla Research Center donated a large portion of its inventory of disposable gloves to California healthcare workers in local area hospitals, and Lundbeck’s U.S. home office donated PPE to a local community center dedicated to helping people with developmental disabilities be fully included in the community and achieve personal success.


Lundbeck is partnering with Mental Health America (MHA) on a groundbreaking initiative that will help identify mental illness hotspots emerging from the pandemic. The bold initiative will analyze the extensive data set generated by MHA’s online mental health screenings, plus publicly available screening data sets, to create a nationwide mental health dashboard. Real-time analysis will allow communities to identify hotspots and react quickly; and the population-based insights can help policymakers, communities and health care providers allocate the right resources, address health disparities and tailor interventions as needed.

Lundbeck provided seed funding and is serving as founding partner for this innovative national dashboard. While the initiative will focus on identifying pandemic-related mental illness spikes to start, it can also be applied to future high-impact events, such as natural disasters and community violence. The dashboard is being built with a particular focus on health equity so that the needs of all communities can be identified and best met.


Lundbeck understands that brain diseases don’t pause for a pandemic. As a leader in brain health, Lundbeck has focused its efforts on addressing the mental health and neurological impacts of COVID-19. The company is working to support communities that may be most impacted by the COVID-19 outbreak. In partnership with patient advocacy group partners, the company is sharing resources and information to help people who may be struggling with social isolation and mental health impacts of the pandemic. The company is also taking steps to address racial disparities in healthcare—disparities that have been highlighted by the pandemic’s disproportionate toll on communities of color—working in collaboration with migraine and mental health patient groups to understand and address barriers to care.


Anchor ID: merck
Research and Development

Merck and Ridgeback Biotherapeutics announced the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of COVID-19 infection. The global study is enrolling individuals who are at least 18 years of age and reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms. For more information on the molnupiravir MOVe-AHEAD clinical trial, visit or


The company has provided a half a million (500,000) personal protective masks to New York City for use as part of urgent efforts to address the outbreak in New York. The company has also donated 300,000 masks for New Jersey.

Additionally, through Merck for Mothers, the company’s global initiative to help end preventable maternal deaths, the company provided $3 million to help health systems better meet the needs of pregnant women before, during and following delivery while tackling COVID-19. Merck for Mothers directed investments to efforts in the U.S. and globally in countries impacted by COVID-19 to help address maternal health challenges that are arising as a result of the pandemic.


The NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV consortium) is a partnership that aims to develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials and regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics. Merck believes a range of medicines and vaccines will be needed to end the pandemic, and they will continue to pursue multiple pathways and collaborate with others.


As a company dedicated to saving and improving lives for more than 100 years, Merck has a special responsibility to help in the fight against COVID-19. Merck has been fully committed to developing an effective response to the COVID-19 pandemic since it was first recognized, and know that success will require global collaboration among countries and companies and more.

Learn more about Merck’s efforts here. Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts. More information here.


Anchor ID: novartis
Research and Development

Novartis is leading, partnering and supporting the identification of therapeutic candidates against coronavirus. They have hand- selected a library of compounds with activity against viral targets of relevance to COVID-19, and they’re working with a consortium of academic institutions and companies that is looking to screen compounds at an appropriate laboratory facility. Novartis is also spearheading a collaborative effort to make direct-acting anti-viral compounds to the coronavirus family, including COVID-19, SARS and MERS. This early-stage drug discovery work builds on the collaboration that formed the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. The new open-science effort will target a piece of machinery that’s shared by several known coronaviruses. The company is supporting COVID-19- related clinical investigations of several Novartis medicines. In our labs, we have started a collaborative, longer-term drug discovery effort to develop first oral medicines for COVID-19 and other coronaviruses.


Novartis has made contributions upwards of USD 40 million to over 60 projects around the world that support local communities impacted by this crisis. These include major donations to strengthen medical infrastructure and provide on-site support in many countries. In addition, Novartis and the Novartis US Foundation have also established $5 million U.S. COVID-19 Community Response Fund for immediate response and recovery efforts related to the pandemic in U.S. communities.


The company is undertaking several efforts to leverage their capabilities in discovery, development and scale-up manufacturing. The company announced manufacturing agreements with BioNtech to provide manufacturing capacity for a COVID-19 vaccination at its site in Stein, Switzerland, as well as an alliance with CureVac to manufacture COVID-19 vaccine candidate in Europe. In addition, Novartis is active in several key cross-industry research initiatives, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard as well as a COVID-19 directed partnership supported by the Innovative Medicines Initiative (IMI). Novartis has also announced a collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19. Furthermore, Novartis Gene Therapies entered into a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to produce its novel genetic COVID-19 vaccine candidate called AAVCOVID8.


In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus pandemic.

To sustain access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19 and entered into a partnership with US-based Civica Rx to support stable supply of essential generic hospital medicines. We are making 15 drugs that treat key symptoms of COVID-19 available to low-and lower-middle income countries at zero profit until a vaccine or curative treatment is available.

More information about the Novartis response to COVID-19 is available on and


Anchor ID: otsuka

The Sozosei Foundation, a charitable organization recently established by Otsuka America Pharmaceutical, Inc., has committed $500,000 in aggregate donations to five local charities in the central New Jersey and Washington, D.C. areas to support those impacted by the COVID-19 pandemic. The charities selected focus on an array of critical services such as providing meals and housing services to at-risk community members including children and the elderly.

Otsuka employees have also mobilized to secure and deliver critical personal protective equipment (PPE) to local health organizations in greatest need. Otsuka has donated more than 3,000 pieces of PPE equipment, including 2,360 medical grade N95 respirator masks, to the New Jersey Office of Emergency Management and directly to frontline and hardest hit hospitals such as Holy Name Hospital in Teaneck, NJ. Otsuka employees also delivered more than 75 cases of bottled water to local EMTs including Princeton First Aid & Rescue Squad and the Rockville Volunteer Fire Department. The Company has also donated 94 iPads to charitable organizations who will distribute them to institutions in greatest need, so that families affected by COVID-19 can connect with their loved ones.


When global healthcare needs arise, we believe in ensuring our industry is part of the solution. We are humbled to announce that our Sozosei Foundation will commit $100,000 to the American India Foundation’s Covid response fund in support of this belief. Their response is focused on aligning resources to meet the acute healthcare infrastructure shortage, keeping frontline workers safe, and supporting greater education and awareness efforts to combat the spread of infections. Every day counts, now more than ever, and we are eager to lean in and help.


Anchor ID: pfizer
Research and Development

COMIRNATY® is the world’s first COVID-19 vaccine ever to receive U.S. Food and Drug Administration (FDA) approval for the prevention of COVID-19 in individuals 16 years of age and older. It is also the first vaccine to receive Emergency Use Authorization (EUA) for a booster dose for individuals 12 years of age and older. In addition, it is authorized for eligible individuals 18 and older who have completed primary vaccination with a different authorized COVID-19 vaccine. COMIRNATY has been available under EUA since December 2020. Today, the EUA covers all individuals 5 years of age and older. Pfizer and BioNTech continue to study the vaccine in children younger than 5 years old.

To secure full FDA approval, Pfizer and BioNTech submitted a comprehensive data package that included longer-term follow-up data from the pivotal Phase 3 clinical trial that enrolled more than 46,000 participants. In the study, the vaccine’s high efficacy and favorable safety profile were observed up to six months after the second dose. The data also showed that the vaccine is well-tolerated across all populations, including the ethnic minorities who have been disproportionally affected by the virus. The trial was closely monitored by an independent Data Monitoring Committee, an outside group of experts monitoring for adverse events. Pfizer and BioNTech scientists remain committed to staying ahead of the virus. They continue to study the long-term efficacy of the vaccine against variants, the need for boosters across all population groups, and new formulations.

In December 2021, Pfizer’s PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) became the first FDA-authorized oral treatment for mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older who are at high risk for progression to severe COVID-19, including hospitalization or death. The EUA is based on clinical data showing PAXLOVID reduced the risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to a placebo. PAXLOVID is currently authorized for conditional or emergency use in several countries across the globe.


Building on its longstanding commitment to fight infectious diseases, Pfizer and The Pfizer Foundation* announced in April 2020 $40 million in medical and charitable cash grants to U.S. and global partners to help combat the effects of the pandemic both at home and abroad. To date, donations have reached more than 165 partners worldwide.

In the largest humanitarian relief effort in Pfizer’s history, the company announced in May 2021, a donation of $70 million worth of medicine to India, to ensure that every public hospital across the country has access to certain medications free of charge for a three-month period. The Pfizer Foundation is also donating to humanitarian organizations directly working in India by providing essential equipment such as ventilators, oxygen concentrators, and consumables across large government hospitals in Delhi and Maharashtra.

Under a collaboration agreement with various governments and the United Nations High Commissioner for Refugees (UNHCR), Pfizer and BioNTech will donate back at least 800,000 doses of the COVID-19 vaccine administered to refugees in Jordan and Lebanon, as part of those countries’ vaccination programs.

Pfizer and the UPS Foundation are committed to accelerate the equitable distribution of COVID-19 vaccinations. The UPS Foundation is donating freezers to countries that need assistance to build out their ultra-cold chain capacity. Pfizer is also taking steps to provide global health stakeholders with resources and expertise to help them strengthen health care systems to facilitate COVID-19 vaccine deployments.

*The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.


Pfizer and BioNTech continue to expand and enhance their COVID-19 vaccine supply chain by expanding existing facilities, adding more suppliers, and bringing on additional sites and contract manufacturers. The companies announced important collaborations to manufacture and distribute the vaccine for Africa and Latin America, bringing its network to span four continents and more than 20 manufacturing facilities.

In late 2021, Pfizer and BioNTech announced a partnership with drone delivery service Zipline, Inc. to distribute vaccines requiring cold chain to some of the most remote areas of Africa. Zipline successfully completed the first long-range drone delivery of both authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) in Ghana in early November. Zipline plans to replicate this novel delivery model in other countries, moving next to Nigeria.


Pfizer and BioNTech manufactured more than 3 billion doses of the Pfizer-BioNTech COVID-19 Vaccine in 2021 and expect to manufacture an additional 4 billion doses in 2022. As of January 2022, the companies have shipped more than 2.6 billion vaccines to 166 countries and territories in every region of the world.

The companies are firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world. To that end, the companies are actively working with governments and health partners worldwide and have pledged to provide two billion doses to low- and middle-income countries in 2021 and 2022 – at least one billion each year. This includes direct supply agreements with individual country governments; agreements to supply one billion doses to the U.S. Government at a not-for-profit price, which the government will, in turn, donate to the African Union and the COVAX 92 Advanced Market Commitment (AMC) countries; and a direct supply agreement with COVAX for the requested 40 million doses in 2021.

As it relates to PAXLOVID, Pfizer is committed to delivering 20 million treatment courses to the U.S. government in 2022. The Company is manufacturing a total of 120 million treatment courses globally this year. Pfizer has signed a voluntary license agreement with the Medicines Patent Pool (MPP) for its oral treatment to help expand access, pending country regulatory authorization or approval, in 95 low- and middle-income countries that account for approximately 53% of the world’s population.

Pfizer continues its arduous work to ensure that Science Will Win in the battle against COVID-19.


Anchor ID: sanofi
Research and Development

Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi is collaborating with BARDA, expanding the company’s long-standing partnership with the Authority. Sanofi will use its recombinant DNA platform to produce a 2019 novel coronavirus vaccine candidate. The recombinant technology produces an exact genetic match to proteins found on the surface of the virus. The DNA sequence encoding this antigen will be combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product, and used to rapidly produce large quantities of the coronavirus antigen which will be formulated to stimulate the immune system to protect against the virus.

The company is also collaborating with Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, where Sanofi is combining its deep vaccine expertise and support with Translate Bio's messenger RNA platform to discover, design, and manufacture a number of SARS-CoV-2 vaccine candidates.

Additionally, Sanofi and GSK have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US. GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

Sanofi has signed an agreement with Luminostics to evaluate a collaboration a unique self-testing solution for covid-19, using Luminostics’ innovative technology. Luminostics would contribute its proprietary technology for consumer-diagnostics for covid-19 testing while Sanofi would bring its clinical research testing experience and capabilities. the goal is to provide a smartphone-based solution that eliminates the current need for healthcare professional administration or laboratory.

Sanofi is working to maintain the supply of all of their medicines and vaccines through close collaboration with their suppliers throughout the world. Their global network of manufacturing plants is operational and the diversity of our global sourcing helps ensure business continuity across all our product lines. At this time, Sanofi does not anticipate shortages for patients resulting from the COVID-19 situation.


Sanofi is also contributing towards those on the front lines. Sanofi China donated 1 million RMB to the Chinese Red Cross Foundation to purchase relevant equipment and supplies for the epidemic area, including protective suits, goggles, masks, gloves, and disinfection equipment. Sanofi Pasteur China donated virus testing devices (throat swabs) worth 500 thousand RMB to Hubei Provincial CDC - Center for Diseases Control and prevention. Sanofi has also contributed $450,000 to humanitarian aid organizations who are working on the frontlines and with the free health clinics across the U.S., and to community organizations helping those in need.

In addition to donating to relief efforts in the communities where we live and work, Sanofi employees around the country have mobilized to volunteer their medical expertise during the COVID-19 pandemic. Any employee who is a licensed medical professional is able to support their community hospital, relief organization, local testing site and more all while maintaining their Sanofi pay and benefits.


Sanofi is collaborating with BARDA, expanding the company’s long-standing partnership with the Authority. The company is also collaborating with Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company. Additionally, Sanofi and GSK have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi has signed an agreement with Luminostics to evaluate a collaboration a unique self-testing solution for covid-19, using Luminostics’ innovative technology. Sanofi is also working to maintain the supply of all of their medicines and vaccines through close collaboration with their suppliers throughout the world.

Sunovion Pharmaceuticals

Anchor ID: sunovion_pharmaceuticals

Sunovion Pharmaceuticals has directed support to first responders, health care workers, and people and communities vulnerable to the physical and mental health impacts of COVID-19. Sunovion has provided a significant donation to the Center for Disaster Philanthropy (CDP) COVID-19 Response Fund. This fund supports nonprofit organizations responding to the pandemic among the most vulnerable populations, as well as preparedness, containment, response and recovery activities for those affected and for the responders.

In partnership with MassBio, Sunovion contributed to the Massachusetts Emergency Management Agency (MEMA) to bring donated medical supplies and resources to the state’s health care institutions so that they can continue to test and treat patients with COVID-19. The company donated cases of PPE including respirators, masks, safety goggles and gloves, as well as protective suits, gowns and shoe covers. In New Jersey, Sunovion donated safety masks to the Office of Emergency Management for distribution to the health care system. In Canada, Sunovion has joined forces with Innovative Medicines Canada to set up a COVID-19 fund to support the most urgent needs and communities across the country, beginning with a shipment of safety masks for front-line health care providers. Additionally, following a call from the government, a number of Sunovion’s UK team members are serving as volunteers to support the community and the National Health Service (NHS).

In the U.S., Sunovion has partnered with its food service vendor to provide food donations to the United Way of Tri-County and has provided financial support to the Greater Boston Food Bank and Community Foodbank of New Jersey, which have a key role in distributing food and grocery products to member agencies that serve people experiencing food insecurity throughout their respective communities. In the UK, Sunovion has delivered food donations to a food bank in London.


Sunovion Pharmaceuticals is committed to giving back in the communities where the company’s employees work and live. As the COVID-19 situation evolved, Sunovion mobilized to contribute to community relief efforts and assist with medical supply donations to address increasing health care needs.


Anchor ID: takeda
Research and Development

Takeda and CSL Behring co-founded the CoVIg-19 Plasma Alliance with other leading global and regional manufacturers of plasma-derived therapies. Together, the Alliance members collaborated to develop and manufacture an investigational non-branded plasma-derived hyperimmune globulin (H-Ig) medicine, referred to as CoVIg-19 for adults hospitalized with COVID-19 at risk for serious complications. The H-Ig was evaluated in a multi-national Phase 3 clinical trial funded by the National Institute of Allergy and Infectious Disease (NIAID) of the U.S. National Institutes of Health (NIH) that was completed in March 2021. While the study did not meet its endpoints, the program has contributed to the scientific understanding of antibody-based treatment to address the virus and highlighted the broader therapeutic value and importance of plasma to treat rare and complex, chronic diseases. Takeda is grateful for the many patients, plasma donors, colleagues, collaborators and external partners including the NIH/NIAID and global regulatory authorities, who made this program possible. Plasma is a lifeline for thousands of people with rare and complex, chronic diseases who rely on plasma-derived medications. The need for human plasma is more urgent than ever, and Takeda encourages healthy individuals to consider donating.


Takeda has donated more than $6.25 million dollars to organizations in the United States to help those impacted by COVID-19 and to support organizations helping the communities they serve.


Takeda’s R&D efforts to address the COVID-19 pandemic have focused on researching novel approaches to treating future pandemics, investigating ways to repurpose marketed products and programs in development as potential treatments, and participating in industry-wide collaborations and data sharing initiatives.

Takeda helped establish the COVID R&D Alliance of more than 20 leading life science companies collaborating to accelerate the development of clinical repurposing and trial acceleration, pre-clinical repurposing, data sharing, and future pandemic preparedness. Takeda also joined other alliances and partnerships including the Innovative Medicines Initiative (IMI) CARE consortium, a public-private partnership to accelerate the discovery and development of COVID-19 treatments, and the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, a public-private partnership to develop a coordinated research strategy for prioritizing development of the most promising treatments and vaccines.

Takeda has partnered with the Government of Japan, Novavax and Moderna, to help accelerate the availability of COVID-19 vaccines. Through the collaboration with Novavax, Takeda is building on its well-established manufacturing and supply capabilities and developing and commercializing Novavax’ vaccine candidate in Japan for the pandemic and beyond. The company is also importing and distributing Moderna‘s COVID-19 vaccine as part of a three-way partnership with Moderna and the Government of Japan’s Ministry of Health Labour and Welfare. Takeda also entered into an agreement with IDT Biologika GmbH (IDT) to utilize capacity for three months at IDT previously reserved for Takeda’s dengue vaccine candidate, to manufacture the single-shot COVID-19 vaccine developed by Janssen, the Pharmaceutical Companies of Johnson & Johnson. The three-month period is now complete.

Takeda supports our partners and alliances in a shared goal to rapidly discover, develop and deliver effective treatments and vaccines for COVID-19 and ensure preparedness for future pandemics.


Anchor ID: ucb
Research and Development

Through UCB’s digital business transformation, the company digitized its clinical study protocols and has expanded the use of decentralized clinical trials to develop new medicines, resulting in continuity of patient care through remote visits even during the COVID-19 pandemic. Gaining real-time access to feedback from patients enrolled in its clinical trials is important, and UCB often uses patient experience surveys to help better understand the patient experience.

As members of the COVID R&D Alliance, UCB, along with two other members of the alliance, announced the first patient enrolled in the COMMUNITY Trial (COVID-19 Multiple Agents and Modulators Unified Industry Members). COMMUNITY is a randomized, double-blind, placebo-controlled, adaptive platform trial that enables an array of therapeutic candidates to be studied in hospitalized COVID-19 patients.


UCB supported COVID relief efforts locally and globally through donations and direct assistance to patients and partners. The company stepped up contributions to organizations working on the front lines of the COVID-19 response, supporting more than 30 organizations across the United States and contributing more than $1 million around the world. Some organizations that UCB was honored to support include hospitals, volunteer and charity organizations, food funds and pantries, and local organizations and businesses that support those on the front lines of caring for COVID-19 patients.

The UCB Community Health Fund was launched in 2020 in response to the COVID-19 pandemic. The fund, managed by the King Baudouin Foundation, aims to address health disparities among vulnerable populations. As part of 50 organizations worldwide receiving funding totaling $2.89 million, the Fund recently awarded donations to seven U.S.-based nonprofit organizations focused on supporting vulnerable young people impacted by COVID-19.

Further, UCB produced and donated hydro-alcoholic solution, donates personal protective equipment to health care authorities and local hospitals, and supports UCB’s health care professionals who wish to volunteer their expertise, in line with local government needs and guidance. UCB also offers expertise to increase local testing capabilities where the company has lab facilities. UCB’s research facility in Bedford, Massachusetts, donated safety glasses, gloves, disposable lab coats, protective suits and gowns, and bags of strip PCR tubes to be used by health care institutions and researchers in Massachusetts to test and treat patients with COVID-19. In addition, the team in UCB’s Raleigh, North Carolina, office supported STEM classrooms in their local community by donating more than 40 boxes and four shopping carts full of extra office supplies to go to teachers at more than 15 schools preparing to return to in-person classes.


UCB is contributing to basic research and treatment development, working with the Seattle Structural Genomics Center for Infectious Disease in the United States, Diamond Light Source in the U.K. and the University of Oxford to research COVID-19 for treatment and vaccine development.

UCB is a member of the COVID R&D Alliance, a group of more than 20 leading pharmaceutical and biotech companies that are devoting significant time, insights and company resources to speed the development of potential therapies, novel antibodies and antiviral therapies for COVID-19 and its related symptoms.

In addition, as part of the COVID Moonshot project, UCB’s medicinal and computational chemists contributed compound designs to this worldwide open-science project to create an orally bioavailable antiviral for COVID-19—with the most potent series of compounds coming from UCB designs.


Patients are at the heart of everything UCB does, and the company is committed to helping those impacted by COVID-19 as well as leveraging scientific expertise and resources to play its part in the global response.

UCB has been making ongoing adjustments to ensure continuous care for patients during this time of great isolation. One way is through UCB’s nurse support line program, in which nurses provide one-on-one, personalized virtual support to patients, including stress management and wellness tips, education and training, and help with uninterrupted access to prescribed medications. In addition, ucbCARES stands ready to support patients, their caregivers and health care providers.

Also, UCB is focused on supporting its employees through its first Employee Hardship Fund, which provides financial assistance to UCB employees experiencing severe and unusual financial hardship due to the COVID-19 crisis. Further, UCB offers all employees and their household members access to a confidential mental health support hotline.
Find the latest on UCB’s response here.

Learn more about our efforts to combat coronavirus